AL-'AQAR HEALTHCARE REIT |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 MYR | 0.00% |
|
+0.78% | +4.84% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Specialized REITs
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.84% | 233M | - | ||
| +3.91% | 693M | C+ | ||
| -6.42% | 612M | - | - | |
| -14.18% | 581M | - | - | |
| -3.27% | 417M | - | - | |
| -13.05% | 396M | - | - | |
| -22.80% | 319M | - | - | |
| -10.83% | 294M | - | - | |
| +0.16% | 234M | - | - | |
| -22.30% | 187M | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- ALAQAR Stock
- Ratings Al-'Aqar Healthcare REIT
